3-苄基-4-甲氧基-4-氧代丁酸 | 651013-72-8

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 中文名称: 3-苄基-4-甲氧基-4-氧代丁酸
• 英文名称: (+/-)-2-benzylsuccinic acid 1-methyl ester
• 英文别名: 2-benzyl-4-hydrogen-1-methylsuccinate；3-Benzyl-4-methoxy-4-oxobutanoic acid
• CAS: 651013-72-8
• 化学式: C₁₂H₁₄O₄
• mdl: MFCD27923800
• 分子量: 222.241
• InChiKey: BUNMUVFKMIOEQU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  16
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.333
• 拓扑面积：
  63.6
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  3-苄基-4-甲氧基-4-氧代丁酸 在 三氟乙酸 、 三氟乙酸酐 作用下， 反应 8.0h， 以70%的产率得到methyl 4-oxo-1,2,3,4-tetrahydronaphthalene-2-carboxylate
  参考文献：
  名称：

  Kinetic resolution of 3-hydroxymethylbenzocycloalkanols by selective asymmetric hydrogen-transfer oxidation

  摘要：

  Kinetic resolution of 3-hydroxymethylbenzocycloalkanols was performed by selective asymmetric hydrogen-transfer oxidation using the Ru(II)-(S,S)-TsDPEN catalyst. Thus, several 3-hydroxymethyl-1-tetralols 7a-d afforded (1R,3R)-3-hydroxymethyl-1-tetralols (1R,3R)-7a-d and (S)-3-hydroxymethyl-1-tetralones (S)-9a-d, and 3-hydroxymethyl-1-indanol 7e gave (1R,3S)3-hydroxymethyl-1-indanol (1R,3S)-7e and (R)-3-hydroxymethyl-1-indanone (R)-9e, with high enantioselectivities. (C) 2003 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tetasy.2003.08.016
• 作为产物：
  描述：

  (E)-3-(methoxycarbonyl)-4-phenylbut-3-enoic acid 在 palladium on activated charcoal 氢气 作用下， 以 甲醇 为溶剂， 反应 3.0h， 以92%的产率得到3-苄基-4-甲氧基-4-氧代丁酸
  参考文献：
  名称：

  Kinetic resolution of 3-hydroxymethylbenzocycloalkanols by selective asymmetric hydrogen-transfer oxidation

  摘要：

  Kinetic resolution of 3-hydroxymethylbenzocycloalkanols was performed by selective asymmetric hydrogen-transfer oxidation using the Ru(II)-(S,S)-TsDPEN catalyst. Thus, several 3-hydroxymethyl-1-tetralols 7a-d afforded (1R,3R)-3-hydroxymethyl-1-tetralols (1R,3R)-7a-d and (S)-3-hydroxymethyl-1-tetralones (S)-9a-d, and 3-hydroxymethyl-1-indanol 7e gave (1R,3S)3-hydroxymethyl-1-indanol (1R,3S)-7e and (R)-3-hydroxymethyl-1-indanone (R)-9e, with high enantioselectivities. (C) 2003 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tetasy.2003.08.016

文献信息

• Synthesis of 2-oxoglutarate derivatives and their evaluation as cosubstrates and inhibitors of human aspartate/asparagine-β-hydroxylase
  作者：Lennart Brewitz、Yu Nakashima、Christopher J. Schofield

  DOI：10.1039/d0sc04301j

  日期：——

  natural product present in human nutrition, was the most efficient alternative cosubstrate identified; crystallographic analyses reveal the binding mode of (R)-3-methyl-2OG and other 2OG derivatives to AspH and inform on the balance between turnover and inhibition. The results will enable the use of 2OG derivatives as mechanistic probes for other 2OG utilizing enzymes and suggest 2-oxoacids other than

  2-氧戊二酸 (2OG) 参与生物过程，包括 2OG 加氧酶催化的氧化反应，它是 2OG 加氧酶的共底物。真核生物 2OG 加氧酶在胶原蛋白生物合成、脂质代谢、DNA/RNA 修饰、转录调节和缺氧反应中发挥作用。天冬氨酸/天冬酰胺-β-羟化酶 (AspH) 是一种人 2OG 加氧酶，催化内质网表皮生长因子样结构域 (EGFD) 中 Asp/Asn 残基的翻译后羟基化。 AspH 具有化学意义，因为它的 Fe( II ) 辅因子由两个而不是典型的三个残基络合。 AspH 在缺氧情况下上调，是癌细胞表面的预后标志物。我们描述了关于其天然 2OG 共底物的衍生物如何调节 AspH 活性的研究。据报道，通过氰基硫内鎓中间体进行 C3-和/或 C4-取代的 2OG 衍生物的有效合成。对 >30 2OG 衍生物进行的基于质谱的 AspH 测定表明，某些衍生物通过与 2OG 竞争来有效抑制 AspH，这
• Nitrogenous heterocyclic derivative, medicinal composition containing the same, medical use thereof, and intermediate therefor
  申请人：Nishimura Toshihiro

  公开号：US20050049203A1

  公开（公告）日：2005-03-03

  The present invention provides nitrogen-containing heterocyclic derivatives represented by the general formula: wherein X 1 and X 3 independently represent N or CH; X 2 represents N or CR 2 ; X 4 represents N or CR 3 ; and with the proviso that one or two of X 1 , X 2 , X 3 and X 4 represent N; R 1 represents a hydrogen atom, a halogen atom, a lower alkyl group, a lower alkoxy group, a lower alkylthio group, a lower alkoxy-substituted (lower alkyl) group, a lower alkoxy-substituted(lower alkoxy) group, a lower alkoxy(lower alkoxy) -substituted (lower alkyl) group, a cyclic lower alkyl group, a halo(lower alkyl) group or a group represented by the general formula: HO-A—wherein A represents a lower alkylene group, a lower alkyleneoxy group or a lower alkylenethio group; R 2 represents a hydrogen atom, a halogen atom, a lower alkyl group, a cyclic lower alkyl group, a lower alkoxy group, an amino group, a (lower acyl)amino group, a mono(lower alkyl)amino group or a di(lower alkyl)amino group; and R 3 represents a hydrogen atom or a lower alkyl group, or pharmaceutically acceptable salts thereof, or prodrugs thereof which are useful as agents for the prevention or treatment of a disease associated with hyperglycemia such as diabetes, diabetic complications or obesity, pharmaceutical compositions comprising the same, and pharmaceutical uses and production intermediates thereof.

  本发明提供了一种以通式表示的含氮杂环衍生物： 其中，X1和X3独立地表示N或CH；X2表示N或CR2；X4表示N或CR3；并且假定X1、X2、X3和X4中的一个或两个表示N；R1表示氢原子、卤素原子、低碳基、低烷氧基、低硫代烷基、低烷氧基取代的（低烷基）基团、低烷氧基取代的（低烷氧基）基团、低烷氧基（低烷氧基）取代的（低烷基）基团、环状低烷基、卤素（低烷基）基团或由通式HO-A-表示的基团，其中A表示低碳亚烷基、低碳亚烷氧基或低碳亚烷硫基；R2表示氢原子、卤素原子、低碳基、环状低碳基、低烷氧基、氨基、（低酰基）氨基、单（低烷基）氨基或双（低烷基）氨基；R3表示氢原子或低碳基，或其药学上可接受的盐，或其前药，其作为预防或治疗与高血糖相关的疾病，如糖尿病、糖尿病并发症或肥胖症的药剂，包括这些药剂的制剂和制备中间体。
• INHIBITORS OF ANTIGEN PRESENTATION BY MHC CLASS II MOLECULES
  申请人：Olson Gary Lee

  公开号：US20120252734A1

  公开（公告）日：2012-10-04

  The present invention relates to compounds, pharmaceutical compositions containing such compounds and methods for their use. In particular, the compounds of the invention are useful for the treatment or prevention of diseases associated with T cell proliferation such as autoimmune diseases and disorders.

  本发明涉及化合物、含有这种化合物的制药组合物以及它们的使用方法。特别地，本发明的化合物对于治疗或预防与T细胞增殖相关的疾病，如自身免疫性疾病和紊乱，是有用的。
• COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS FOR USE IN TREATING METABOLIC DISORDERS
  申请人：Hoveyda Hamid

  公开号：US20110230477A1

  公开（公告）日：2011-09-22

  The present invention is directed to novel compounds of formula (I) and their use in treating metabolic diseases.

  本发明涉及式（I）的新化合物及其在治疗代谢性疾病方面的应用。
• Aminoalkylaminocarbonyl aminodiol amino acid derivatives as anti-hypertensive agents
  申请人：G.D. Searle & Co.

  公开号：EP0349922A2

  公开（公告）日：1990-01-10

  Non-peptidyl compounds characterized generally as aminoalkylaminocarbonyl aminodiol derivatives of amino acids are useful as renin inhibitors for the treatment of hypertension. Compounds of particular interest are of the formula wherein X is selected from oxygen atom and methylene; wherein each of R1 and R9 is independently selected from hydrido, methyl, ethyl, t-butyloxycarbonyl; and methoxymethylcarbonyl; wherein R2 is selected from hydrido, methyl, ethyl and isopropyl; wherein R3 is selected from benzyl, phenethyl, pyridylmethyl and 2-pyridylethyl; wherein each of R4 and R6 is independently selected from hydrido and methyl; wherein R7 is cyclohexylmethyl; wherein R8 is isobutyl; wherein each of R11 and R12 is hydrido; wherein m is zero or one and n is a number selected from zero through five; or a pharmaceutically-acceptable salt thereof; with the proviso that where m is zero, then Rs is selected from imidazolemethyl, thiazolemethyl and isobutyl; and with the further proviso that when m is one, then Rs is methyl or ethyl.

  一般表征为氨基酸的氨基烷基氨基羰基氨基二醇衍生物的非肽类化合物可作为治疗高血压的肾素抑制剂。特别令人感兴趣的化合物如下式所示 其中 X 选自氧原子和亚甲基；其中 R1 和 R9 各自独立地选自水缩基、甲基、乙基、叔丁氧基羰基和甲氧基甲基羰基；其中 R2 选自水缩基、甲基、乙基和异丙基；其中 R3 选自苄基、苯乙基、吡啶甲基和 2-吡啶乙基；其中 R4 和 R6 各自独立地选自水缩基和甲基；其中 R7 是环己基甲基；其中 R8 是异丁基；其中 R11 和 R12 各自是氢rido；其中 m 是零或一，n 是选自零到五的数字；或其药学上可接受的盐；但条件是，当 m 为零时，Rs 选自咪唑甲基、噻唑甲基和异丁基；进一步的条件是，当 m 为一时，Rs 是甲基或乙基。